New Study.... Saw Palmetto Inhibits DHT

JohnnySeville

Established Member
Reaction score
0
Lots of speculation has been prevalent concerning the use of Saw Palmetto. It has been a well known fact that use of saw palmetto extract can be beneficial to those with prostatic hypertrophy, but the method of action has been debated. This study sheds new light on the method of action that this extract exerts, namely by inhibiting the 5AR enzyme, the enzyme that converts testosterone into dihydrotestosterone (DHT). One can only speculate that through this action it would have beneficial effects on hair growth as other 5AR inhibitors, ie finasteride etc.

*************************************************************


The ability for Saw Palmetto to inhibit DHT has been the subject of much speculation. It has long been established that Saw Palmetto has beneficial effects on the prostate when given to men with an enlarged prostate (BPH). The question of exactly how Saw Palmetto works has never been fully resolved.

Some research has suggested it may lower DHT, but the studies have been contradictory leaving many people with the impression that Saw Palmetto has no effect on DHT production.

Well now a study done on mice has provided clear evidence that Saw Palmetto does in fact lower DHT production.

Researchers in Oregon were attempting to establish whether Saw Palmetto has any benefit in treating prostate cancer tumors. The researchers tested the Saw Palmetto extract on genetically-engineered mice whose prostate mimics that of a human - these mice are used to test prostate treatments because they respond to drugs in the same way as humans do.

In the study the mice were given one of two doses of Saw Palmetto extract, either 50 mg/kilogram/day or 300mg/kilogram/day for 3 or 6 months.

After the conclusion of the trial the researchers examined the prostates of the mice and found that the mice who had received the equivalent of 300mg/kilogram/day had significantly reduced amounts of dihydrotestosterone (DHT) in their prostate tissue.

In addition to this, their prostate tumors had also been reduced in size.

Based on this data the researchers were then able to conclude that Saw Palmetto does indeed reduce the production of DHT by inhibiting the 5-alpha reductase enzyme, the enzyme that converts testosterone into dihydrotestosterone (DHT).

*************************************************************

Effects of dietary saw palmetto on the prostate of transgenic adenocarcinoma of the mouse prostate model (TRAMP)

Wadsworth TL, Worstell TR, Greenberg NM, Roselli CE.
Department of Physiology and Pharmacology, Oregon Health and Science University, Portland, Oregon.

BACKGROUND: Several of the proposed mechanisms for the actions of the liposterolic extract of saw palmetto (SPE) are exerted on known risk factors for prostate cancer (CaP). This study investigated whether SPE could prevent the progression of CaP in a transgenic adenocarcinoma of the mouse prostate (TRAMP) model. METHODS: Two different doses of SPE designed to deliver 50 mg/kg/day SPE and 300 mg/kg/day SPE were administered in a custom diet to TRAMP mice for 12 or 24 weeks. Body and organ weights were used to evaluate toxicity, and radioimmunoassay was used to measure plasma and tissue androgen levels to monitor effects of SPE on 5alpha reductase activity. Prostate tissues were evaluated histologically to determine the effect of treatment on tumor grade, cell proliferation, and apoptosis. RESULTS: Treatment with 300 mg/kg/day SPE from 4 to 24 weeks of age significantly reduced the concentration of 5alpha-dihydrotestosterone (DHT) in the prostate and resulted in a significant increase in apoptosis and significant decrease in pathological tumor grade and frank tumor incidence. CONCLUSIONS: Dietary supplementation with SPE may be effective in controlling CaP tumorigenesis. SPE suppression of prostatic DHT levels lends support to the hypothesis that inhibition of the enzyme 5alpha-reductase is a mechanism of action of this substance. Prostate (c) 2007 Wiley-Liss, Inc.
 

michael barry

Senior Member
Reaction score
12
Thirty two percent according to this study..................but they dont tell you how much they gave the men in the tests. ....




: Urology. 2001 May;57(5):999-1005. Related Articles, Links


Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens.

Marks LS, Hess DL, Dorey FJ, Luz Macairan M, Cruz Santos PB, Tyler VE.

Urological Sciences Research Foundation, Culver City, California, USA.

OBJECTIVES: To determine the effects of a saw palmetto herbal blend (SPHB) compared with finasteride on prostatic tissue androgen levels and to evaluate needle biopsies as a source of tissue for such determinations. METHODS: Prostate levels of testosterone and dihydrotestosterone (DHT) were measured on 5 to 10-mg biopsy specimens (18-gauge needle cores) in three groups of men with symptomatic benign prostatic hyperplasia: 15 men receiving chronic finasteride therapy versus 7 untreated controls; 4 men undergoing prostate adenomectomy to determine sampling variability (10 specimens each); and 40 men participating in a 6-month randomized trial of SPHB versus placebo, before and after treatment. RESULTS: Prostatic tissue DHT levels were found to be several times higher than the levels of testosterone (5.01 versus 1.51 ng/g), that ratio becoming reversed (1.05 versus 3.63 ng/g) with chronic finasteride therapy. The finasteride effect was statistically significant for both androgens (P <0.01), and little overlap of individual values between finasteride-treated and control patients was seen. In the randomized trial, tissue DHT levels were reduced by 32% from 6.49 to 4.40 ng/g in the SPHB group (P <0.005), with no significant change in the placebo group. CONCLUSIONS: For control versus finasteride-treated men, the tissue androgen values obtained with needle biopsy specimens were similar-both for absolute values and the percentage of change-to those previously reported using surgically excised volumes of prostatic tissue. The quantification of prostatic androgens by assay of needle biopsies is thus feasible and offers the possibility of serial studies in individual patients. The SPHB-induced suppression of prostatic DHT levels, modest but significant in a randomized trial, lends an element of support to the hypothesis that inhibition of the enzyme 5-alpha reductase is a mechanism of action of this substance.

Publication Types:
Clinical Trial
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

PMID: 11337315 [PubMed - indexed for MEDLINE
 

docj077

Senior Member
Reaction score
1
The average person weights 70 kg. That means that a male of average weight will have to take in 21,000 mg per day to achieve the same level of DHT inhibition that they see in mice if one simply adjusts the amount of saw palmetto intake for the increase in body weight in a proportional manner.

That's not even reasonible.


"In the study the mice were given one of two doses of Saw Palmetto extract, either 50 mg/kilogram/day or 300mg/kilogram/day for 3 or 6 months.

After the conclusion of the trial the researchers examined the prostates of the mice and found that the mice who had received the equivalent of 300mg/kilogram/day had significantly reduced amounts of dihydrotestosterone (DHT) in their prostate tissue."
 

wookster

Experienced Member
Reaction score
0
docj077 said:
The average person weights 70 kg. That means that a male of average weight will have to take in 21,000 mg per day to achieve the same level of DHT inhibition that they see in mice if one simply adjusts the amount of saw palmetto intake for the increase in body weight in a proportional manner.

That's not even reasonible.

Some reports say that the active ingredient in saw-palmetto is the beta-sitosterol ...and 300mg of beta sitosterol is roughly equivalent to 3000 times the beta-sitosterol content of a saw-palmetto tablet.

21000/3000 = 7

7 x 300 = 2100

2.1 grams of beta sitosterol per day? :hairy:
 

JohnnySeville

Established Member
Reaction score
0
docj077 said:
The average person weights 70 kg. That means that a male of average weight will have to take in 21,000 mg per day to achieve the same level of DHT inhibition that they see in mice if one simply adjusts the amount of saw palmetto intake for the increase in body weight in a proportional manner.

That's not even reasonible.


"In the study the mice were given one of two doses of Saw Palmetto extract, either 50 mg/kilogram/day or 300mg/kilogram/day for 3 or 6 months.

After the conclusion of the trial the researchers examined the prostates of the mice and found that the mice who had received the equivalent of 300mg/kilogram/day had significantly reduced amounts of dihydrotestosterone (DHT) in their prostate tissue."

I was wondering when someone would make a comment on the amount required in a normal sized person. Perhaps a number of members noticed, but were too lazy to post! :) I have no idea how they came to determine 300mg/kg, perhaps the quality of their extract was poor. Not having the full text article one can only speculate on this.

On the other hand, the following study utilizes a reasonable amount of extract, 320mg, this is commonly taken by just about everyone when supplementing. The results of this study show a substantial reduction of DHT with an increase of T, as is the norm when utilizing any of the other well know 5AR inhibitors ie, finasteride etc.

***********************

Effects of long-term treatment with Serenoa repens (Permixon) on the concentrations and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia
Di Silverio F, Monti S, Sciarra A, Varasano PA, Martini C, Lanzara S, D'Eramo G, Di Nicola S, Toscano V.
Department of Urology, University of Rome La Sapienza, Italy.

BACKGROUND: The n-hexane lipido-sterol extract of Serenoa repens (LSESr, Permixon, Pierre Fabre Medicament, Castres, France), a phytotherapeutic agent used in the treatment of benign prostatic hyperplasia (BPH), has a multisite mechanism of action including inhibition of types 1 and 2 5alpha-reductase and competitive binding to androgen receptors in prostatic cells. Here, the response of testosterone (T), dihydrotestosterone (DHT), and epidermal growth factor (EGF) in BPH tissue of patients treated with LSESr (320 mg/day for 3 months) is analyzed. METHODS: BPH samples were sectioned in periurethral, subcapsular, and intermediate regions: in each region T, DHT, and EGF were determined by radioimmunoassay after purification on celite columns or Sep-pak C18 cartridges. RESULTS: In the untreated group, T, DHT, and EGF presented the highest concentrations in the periurethral region (615 +/- 62 (SE) pg/g tissue, 7,317 +/- 551 pg/g tissue, and 20.9 +/- 3.3 ng/g tissue, respectively) with respect to the peripheral subcapsular region (425 +/- 45 pg/g tissue, 4,215 +/- 561 pg/g tissue, and 10.8 +/- 1.4 ng/g tissue, respectively). In the LSESr-treated group, a statistically significant reduction was observed, mainly in the periurethral region of DHT (2,363 +/- 553 pg/g tissue, P < 0.001) and EGF (6.98 +/- 2.48 ng/g tissue, P < 0.01), with increased T values (1,023 +/- 101 pg/g tissue, P < 0.001). CONCLUSIONS: The decrease of DHT and the rise of T in BPH tissue of patients treated with Permixon confirms the capacity of this drug to inhibit in vivo 5alpha-reductase in human pathological prostate. A marked decrease of EGF, associated with DHT reduction, was also observed. These biochemical effects, similar to those obtained with finasteride, are particularly evident in the periurethral region, whose enlargement is responsible for urinary obstruction, with respect to the subcapsular region. A possible speculation is that the preferential reduction of DHT and EGF content in the periurethral region is involved in the clinical improvement of the obstructive symptoms in BPH during LSESr therapy.

*******************

One more study, showing evidence that saw palmetto extract can have favorable influences on hair growth, though more comprehensive testing would be required to be definitive.

A randomized, double-blind, placebo-controlled trial to determine the effectiveness of botanically derived inhibitors of 5-alpha-reductase in the treatment of androgenetic alopecia

Prager N, Bickett K, French N, Marcovici G.
Clinical Research and Development Network, Aurora, CO, USA.

BACKGROUND: Androgenetic alopecia (Androgenetic Alopecia) is characterized by the structural miniaturization of androgen-sensitive hair follicles in susceptible individuals and is anatomically defined within a given pattern of the scalp. Biochemically, one contributing factor of this disorder is the conversion of testosterone (T) to dihydrotestosterone (DHT) via the enzyme 5-alpha reductase (5AR). This metabolism is also key to the onset and progression of benign prostatic hyperplasia (BPH). Furthermore, Androgenetic Alopecia has also been shown to be responsive to drugs and agents used to treat BPH. Of note, certain botanical compounds have previously demonstrated efficacy against BPH. Here, we report the first example of a placebo-controlled, double-blind study undertaken in order to examine the benefit of these botanical substances in the treatment of Androgenetic Alopecia. OBJECTIVES: The goal of this study was to test botanically derived 5AR inhibitors, specifically the liposterolic extract of Serenoa repens (LSESr) and beta-sitosterol, in the treatment of Androgenetic Alopecia. Subjects: Included in this study were males between the ages of 23 and 64 years of age, in good health, with mild to moderate Androgenetic Alopecia. RESULTS: The results of this pilot study showed a highly positive response to treatment. The blinded investigative staff assessment report showed that 60% of (6/10) study subjects dosed with the active study formulation were rated as improved at the final visit. CONCLUSIONS: This study establishes the effectiveness of naturally occurring 5AR inhibitors against Androgenetic Alopecia for the first time, and justifies the expansion to larger trials.
 
Top